[{"id":"a1ad25fe-9fca-497e-84b3-6dc3bccd8870","acronym":"CHM-2101-001","url":"https://clinicaltrials.gov/study/NCT06055439","created_at":"2023-09-26T16:12:30.309Z","updated_at":"2025-02-25T15:45:14.681Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy","source_id_and_acronym":"NCT06055439 - CHM-2101-001","lead_sponsor":"Chimeric Therapeutics","biomarkers":" CDH17","pipe":" | ","alterations":" CDH1 expression","tags":["CDH17"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 05/15/2024","start_date":" 05/15/2024","primary_txt":" Primary completion: 05/01/2026","primary_completion_date":" 05/01/2026","study_txt":" Completion: 05/01/2027","study_completion_date":" 05/01/2027","last_update_posted":"2025-02-11"},{"id":"8d1ccb5b-f750-498e-b8e0-01cc46ef60cb","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919108","created_at":"2023-06-26T14:09:19.440Z","updated_at":"2024-07-02T16:34:26.575Z","phase":"Phase 2","brief_title":"Neoadjuvant Neratinib in Stage I-III HER2-Mutated Lobular Breast Cancers","source_id_and_acronym":"NCT05919108","lead_sponsor":"Vanderbilt-Ingram Cancer Center","biomarkers":" HER-2 • ER • CDH1","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Nerlynx (neratinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 09/30/2024","start_date":" 09/30/2024","primary_txt":" Primary completion: 04/30/2030","primary_completion_date":" 04/30/2030","study_txt":" Completion: 04/30/2031","study_completion_date":" 04/30/2031","last_update_posted":"2024-06-13"},{"id":"d6f98f26-2498-46cc-812f-de883aab657a","acronym":"PIONEER","url":"https://clinicaltrials.gov/study/NCT03306472","created_at":"2021-01-18T16:19:53.588Z","updated_at":"2024-07-02T16:35:21.649Z","phase":"Phase 2","brief_title":"A Pre-operative Window Study of Letrozole Plus PR Agonist (Megestrol Acetate) Versus Letrozole Alone in Post-menopausal Patients With ER-positive Breast Cancer","source_id_and_acronym":"NCT03306472 - PIONEER","lead_sponsor":"Cambridge University Hospitals NHS Foundation Trust","biomarkers":" HER-2 • ER • CDH1 • CDH2","pipe":" | ","alterations":" ER positive • HER-2 negative • CDH1 expression","tags":["HER-2 • ER • CDH1 • CDH2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e letrozole • megestrol"],"overall_status":"Completed","enrollment":" Enrollment 198","initiation":"Initiation: 07/20/2017","start_date":" 07/20/2017","primary_txt":" Primary completion: 10/31/2022","primary_completion_date":" 10/31/2022","study_txt":" Completion: 10/31/2023","study_completion_date":" 10/31/2023","last_update_posted":"2024-01-30"},{"id":"91561dac-30a2-4a93-98b9-a8a30dc2db38","acronym":"","url":"https://clinicaltrials.gov/study/NCT05411133","created_at":"2022-06-09T13:55:21.916Z","updated_at":"2024-07-02T16:35:22.665Z","phase":"Phase 1","brief_title":"Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients","source_id_and_acronym":"NCT05411133","lead_sponsor":"Arbele Pty Ltd","biomarkers":" CDH17","pipe":" | ","alterations":" CDH1 expression","tags":["CDH17"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • cabotamig (ARB202)"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 05/30/2022","start_date":" 05/30/2022","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-01-23"},{"id":"e6fa6f5f-f47f-4e45-ac2a-8106517e9c98","acronym":"","url":"https://clinicaltrials.gov/study/NCT04021394","created_at":"2021-01-18T19:44:45.886Z","updated_at":"2024-07-02T16:35:51.538Z","phase":"","brief_title":"Influence of EMT on CTCs and Disease Progression in Prostate Cancer","source_id_and_acronym":"NCT04021394","lead_sponsor":"Lawson Health Research Institute","biomarkers":" CDH1 • EPCAM • CDH2 • ZEB1","pipe":" | ","alterations":" AR expression • CDH1 expression • EPCAM expression • ZEB1 expression","tags":["CDH1 • EPCAM • CDH2 • ZEB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AR expression • CDH1 expression • EPCAM expression • ZEB1 expression"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 06/05/2019","start_date":" 06/05/2019","primary_txt":" Primary completion: 04/27/2021","primary_completion_date":" 04/27/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2023-04-04"},{"id":"20481648-b24a-4001-9d26-bf1b3e73c61c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02451553","created_at":"2021-01-18T11:45:16.896Z","updated_at":"2024-07-02T16:36:09.285Z","phase":"Phase 1","brief_title":"Afatinib Dimaleate and Capecitabine in Treating Patients With Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer","source_id_and_acronym":"NCT02451553","lead_sponsor":"University of Washington","biomarkers":" EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS","pipe":" | ","alterations":" EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • NRAS • CDH1 • RAF1 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • BRAF mutation • NRAS mutation • HER-2 mutation • CDH1 expression • CDH1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • capecitabine"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 11/05/2015","start_date":" 11/05/2015","primary_txt":" Primary completion: 04/16/2022","primary_completion_date":" 04/16/2022","study_txt":" Completion: 04/16/2022","study_completion_date":" 04/16/2022","last_update_posted":"2022-06-07"},{"id":"6c5f7ced-a2da-4747-94f7-843dd3dd77c0","acronym":"","url":"https://clinicaltrials.gov/study/NCT02856503","created_at":"2021-01-18T14:01:17.257Z","updated_at":"2024-07-02T16:37:03.723Z","phase":"Phase 1/2","brief_title":"Effect of High Dose Vitamin D on Cancer Biomarkers and Breast Cancer Tumors","source_id_and_acronym":"NCT02856503","lead_sponsor":"Eli Avisar","biomarkers":" EGFR • HER-2 • PGR • AR • CDH1 • VDR","pipe":" | ","alterations":" HER-2 expression • CDH1 expression","tags":["EGFR • HER-2 • PGR • AR • CDH1 • VDR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression • CDH1 expression"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/01/2019","start_date":" 01/01/2019","primary_txt":" Primary completion: 01/01/2023","primary_completion_date":" 01/01/2023","study_txt":" Completion: 01/01/2024","study_completion_date":" 01/01/2024","last_update_posted":"2019-01-18"},{"id":"665a24f0-30ae-47ae-bd4a-55761e74693b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02948075","created_at":"2021-01-18T14:28:35.503Z","updated_at":"2024-07-02T16:37:09.434Z","phase":"Phase 2","brief_title":"Safety and Efficacy of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy","source_id_and_acronym":"NCT02948075","lead_sponsor":"NewVac LLC","biomarkers":" BRCA1 • ERCC1 • CDH1","pipe":" | ","alterations":" BRCA1 expression • CDH1 expression • ERCC1 expression","tags":["BRCA1 • ERCC1 • CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA1 expression • CDH1 expression • ERCC1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • quisinostat (JNJ 26481585)"],"overall_status":"Completed","enrollment":" Enrollment 31","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 06/16/2017","study_completion_date":" 06/16/2017","last_update_posted":"2018-06-27"},{"id":"c64e4a08-e403-4230-ab36-3d42a457255d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00159484","created_at":"2021-01-18T00:32:30.508Z","updated_at":"2025-02-25T15:47:20.936Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Celebrex and EPO906 in Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT00159484","lead_sponsor":"University of Southern California","biomarkers":" CDH1","pipe":" | ","alterations":" CDH1 expression • VEGFA expression","tags":["CDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDH1 expression • VEGFA expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e celecoxib oral • patupilone (EPO 906)"],"overall_status":"Unknown status","enrollment":" Enrollment 75","initiation":"Initiation: 10/01/2004","start_date":" 10/01/2004","primary_txt":" Primary completion: 12/01/2016","primary_completion_date":" 12/01/2016","study_txt":" Completion: 12/01/2017","study_completion_date":" 12/01/2017","last_update_posted":"2017-06-27"},{"id":"fc6018ad-4547-4119-a893-d50b39ee1e4c","acronym":"","url":"https://clinicaltrials.gov/study/NCT00828984","created_at":"2021-01-18T03:09:18.427Z","updated_at":"2024-07-02T16:37:23.311Z","phase":"Phase 2","brief_title":"Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer","source_id_and_acronym":"NCT00828984","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • CDH1 • CASP3 • SNAI1","pipe":" | ","alterations":" EGFR expression • CDH1 expression","tags":["EGFR • CDH1 • CASP3 • SNAI1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CDH1 expression"],"overall_status":"Completed","enrollment":" Enrollment 87","initiation":"Initiation: 10/01/2009","start_date":" 10/01/2009","primary_txt":" Primary completion: 10/01/2014","primary_completion_date":" 10/01/2014","study_txt":" Completion: 10/01/2014","study_completion_date":" 10/01/2014","last_update_posted":"2017-04-18"}]